Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 13 July 2017

Weifa ASA: Record second-quarter revenues driven by pain and cough & cold

Weifa ASA    

Published: 07:30 CEST 13-07-2017 /GlobeNewswire /Source: Weifa ASA / : WEIFA /ISIN: NO0010308240

Weifa ASA: Record second-quarter revenues driven by pain and cough & cold

Oslo, 13 July 2017

  • Record second-quarter revenues of NOK 98.6 million (NOK 95.3 million)
  • All-organic growth of 3.4%
  • Second-quarter adjusted EBITDA of NOK 22.1 million (NOK 18.6 million)
  • Adjusted EBITDA margin of 22.5% (19.5%)
  • Record first-half revenues of NOK 198.2 million (NOK 191.5 million)
  • Organic growth of 3.5%
  • Strong brands secured revenue growth and high market shares in the main categories

Weifa ASA (OSE: WEIFA) had record second-quarter revenues in 2017 on higher sales within pain relief and cough & cold products. Total revenues for the quarter was NOK 98.6 million, representing an all-organic growth of 3.4% compared with the same period of 2016.


EBITDA was NOK 21.1 million (NOK 17.1 million) for the second quarter after NOK 1.1 million (NOK1.4 million) in cost of employee options. The EBITDA margin adjusted for these costs was 22.5% (19.5%). Weifa's portfolio of long-established brands maintained a high market share in all key segments during the quarter.


"We are on track to deliver on our revenue growth ambitions for 2017 with record revenue for both the second quarter and first half of 2017. We continue to develop our leading position in the Norway across our portfolio, and we look forward to developing our Nordic offering going forward" says CEO Kathrine Gamborg Andreassen.


Revenue for the first half of 2017 was NOK 198.2 million, an increase of 3.5% from the same period in 2016. The organic growth was driven by increased demand for pain and cough and cold products.


Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from:



Questions may be submitted live during the presentation.


Please find the report and presentation for the second quarter enclosed. The report and presentation will also be made available on www.weifa.no.


For further information, please contact:


Kathrine Gamborg Andreassen


+47 95 17 86 80



Simen Nyberg-Hansen


+47 98 20 63 55



Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Weifa ASA_2Q 2017_Presentation
Weifa ASA_2Q 2017_Report

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Weifa ASA, Postboks 6733 Etterstad, Oslo NO-0609, Norge
If you would like to unsubscribe and stop receiving these e-mails click here.